Cristin-resultat-ID: 1826988
Sist endret: 15. mars 2021, 10:42
NVI-rapporteringsår: 2021
Resultat
Vitenskapelig artikkel
2021

The short-term impact of methylprednisolone on patient-reported sleep in patients with advanced cancer in a randomized, placebo-controlled, double-blind trial

Bidragsytere:
  • Gunnhild Jakobsen
  • Morten Engstrøm
  • Marianne Jensen Hjermstad
  • Jan Henrik Rosland
  • Nina Kathrine Aass
  • Eva Albert
  • mfl.

Tidsskrift

Supportive Care in Cancer
ISSN 0941-4355
e-ISSN 1433-7339
NVI-nivå 1

Om resultatet

Vitenskapelig artikkel
Publiseringsår: 2021
Publisert online: 2020
Volum: 29
Hefte: 4
Sider: 2047 - 2055
Open Access

Importkilder

Scopus-ID: 2-s2.0-85089890298

Beskrivelse Beskrivelse

Tittel

The short-term impact of methylprednisolone on patient-reported sleep in patients with advanced cancer in a randomized, placebo-controlled, double-blind trial

Sammendrag

Purpose: Although corticosteroids are frequently used in patients with advanced cancer, few studies have examined the impact of these drugs on patient-reported sleep. We aimed to examine the short-term impact of methylprednisolone on patient-reported sleep in patients with advanced cancer. Methods: Patient-reported sleep was a predefined secondary outcome in a prospective, randomized, placebo-controlled, double-blind trial that evaluated the analgesic efficacy of corticosteroids in advanced cancer patients (18+), using opioids, and having pain ≥ 4 past 24 h (NRS 0-10). Patients were randomized to the methylprednisolone group with methylprednisolone 16 mg × 2/day or placebo for 7 days. The EORTC QLQ-C30 (0-100) and the Pittsburgh Sleep Quality Index questionnaire (PSQI) (0-21) were used to assess the impact of corticosteroids on sleep at baseline and at day 7. Results: Fifty patients were randomized of which 25 were analyzed in the intervention group and 22 in the control group. Mean age was 64 years, mean Karnofsky performance status was 67 (SD 13.3), 51% were female, and the mean oral daily morphine equivalent dose was 223 mg (SD 222.77). Mean QLQ-C30 sleep score at baseline was 29.0 (SD 36.7) in the methylprednisolone group and 24.2 (SD 27.6) in the placebo group. At day 7, there was no difference between the groups on QLQ-C30 sleep score (methylprednisolone 20.3 (SD 32.9); placebo 28.8 (SD 33.0), p = 0.173). PSQI showed similar results. Conclusions: Methylprednisolone 16 mg twice daily for 7 days had no impact on patient-reported sleep in this cohort of patients with advanced cancer.

Bidragsytere

Gunnhild Jakobsen

  • Tilknyttet:
    Forfatter
    ved Institutt for klinisk og molekylær medisin ved Norges teknisk-naturvitenskapelige universitet
  • Tilknyttet:
    Forfatter
    ved Kreftklinikken ved St. Olavs Hospital HF

Morten Engstrøm

  • Tilknyttet:
    Forfatter
    ved Institutt for nevromedisin og bevegelsesvitenskap ved Norges teknisk-naturvitenskapelige universitet
  • Tilknyttet:
    Forfatter
    ved Nevroklinikken ved St. Olavs Hospital HF

Marianne Jensen Hjermstad

  • Tilknyttet:
    Forfatter
    ved Avdeling for kreftbehandling ved Oslo universitetssykehus HF
  • Tilknyttet:
    Forfatter
    ved Avdeling for kreftbehandling ved Universitetet i Oslo

Jan Henrik Rosland

  • Tilknyttet:
    Forfatter
    ved Haraldsplass Diakonale sykehus​ ved Private ideelle i Helse Vest
  • Tilknyttet:
    Forfatter
    ved Klinisk institutt 1 ved Universitetet i Bergen

Nina Kathrine Aass

  • Tilknyttet:
    Forfatter
    ved Avdeling for kreftbehandling ved Oslo universitetssykehus HF
  • Tilknyttet:
    Forfatter
    ved Avdeling for kreftbehandling ved Universitetet i Oslo
1 - 5 av 10 | Neste | Siste »